ライフサイエンスコーパス: human insulin

1 ecular weight guests such as proteins (e.g., human insulin).

2 y profiles compared with that of recombinant human insulin.

3 t in birds and fish) augments the potency of human insulin.

4 gic and saturating concentrations of regular human insulin.

5 ein can be used to extend the time action of human insulin.

6 or tetraplex structures in the expression of human insulin.

7 1.35 A, is essentially identical to that of human insulin.

8 -glucose abolished the stimulatory effect of human insulin (1 nM, 8 h) on L-[3H]leucine incorporation

9 was achieved by administering a recombinant human insulin a few hours after Albulin injection in mic

10 ted transgenic potato plants that synthesize human insulin, a major insulin-dependent diabetes mellit

11 We showed previously that ingested human insulin activates the insulin/IGF-1 signaling path

12 of action of [N(epsilon)-palmitoyl Lys(B29)] human insulin administered intravenously was nearly twic

13 hniques [recombinant human (r-human) and its human insulin analog (LysPro)].

14 A recombinant monomeric human insulin analog, which does not bind to the insulin

15 eater than that of an analogous single-chain human insulin analog.

16 ls is to screen the amyloid-forming proteins human insulin and beta(2)-microglobulin for segments tha

17 nstrated that the presence of high levels of human insulin and bovine insulin does not interfere with

18 n glucose stimulation of the implanted mice, human insulin and C-peptide are detected in sera at leve

19 was assessed by measuring the production of human insulin and C-peptide over a period of 3-15 months

20 In vivo function was assessed by measuring human insulin and C-peptide production, and by the abili

21 ncreatic beta cells where it is processed to human insulin and CpepSfGFP.

22 f Chinese hamster ovary cells expressing the human insulin and EGF receptors resulted in a time-depen

23 The effects of human insulin and elevated D-glucose on L-arginine trans

24 imultaneous, direct quantification of intact human insulin and five insulin analogs in human plasma.

25 o islet-like structures capable of producing human insulin and maintaining normoglycemia.

26 glycemic control similar to that of premixed human insulin and may provide tighter glycemic control t

27 ogical efficacy, we used UTMD to deliver RIP-human insulin and RIP-hexokinase I plasmids to islets of

28 t insulin with 40 to 100% of the activity on human insulin, and all mAbs bind proinsulin.

29 is folded in the ER, exported, converted to human insulin, and secreted.

30 venously was nearly twice that of unmodified human insulin, and the plasma half-life was nearly seven

31 eak daf-2 mutants, suggesting that INS-1 and human insulin antagonize DAF-2 insulin-like signaling.

32 t the potency and thermodynamic stability of human insulin are enhanced in concert by substitution of

33 the C-terminal prolyl and lysyl residues of human insulin are inverted, and protamine that is used a

34 ssignment of paired cysteine residues, using human insulin as a model protein.

35 , we characterize the aggregation process of human insulin at acidic pH in the presence of sulfate io

36 ate of the protein, the crystal structure of human insulin at pH 2.1 has been determined to 1.6 A res

37 two class III VNTR constructs linked to the human insulin basal promoter or SV40 heterologous promot

38 educed three out of four disulfide bridges), human insulin, bovine core histones, and human alpha-syn

39 e investigated the fibrillation of monomeric human insulin by monitoring changes in CD, attenuated to

40 With this gene, the secretion of human insulin by the exocrine pancreas normalized elevat

41 This paper describes the binding of human insulin by the synthetic receptor cucurbit[7]uril

42 nsulin derivative octanoyl-N(epsilon)-LysB29-human insulin (C8-HI).

43 insulin/IGF-1 signaling pathway by ingested human insulin can alter NF-kappaB-dependent immunity, an

44 We show here that human insulin can be cocrystallized at preselected ratio

45 Mutations in human insulin cause an autosomal-dominant syndrome of di

46 INS-1res cells with a plasmid containing the human insulin cDNA and expansion of the transfected colo

47 the liver-specific albumin promoter, and the human insulin cDNA modified for furin cleavage compatibi

48 Four lines of transgenic mice harboring a human insulin cDNA with expression driven by the goat be

49 this represents the most efficient route of human insulin chemical synthesis reported to date.

50 ls, is processed and stored as CpepSfGFP and human insulin comprising only approximately 0.04% of tot

51 lin infusion (group 3) achieved steady-state human insulin concentrations of 22,000 plus minus 1,800

52 infusion (group 2) established steady-state human insulin concentrations of 6,300 plus minus 510 pmo

53 nstant whether in the absence or presence of human insulin concentrations sufficient to saturate the

54 is structure leads to a model for fibrils of human insulin consistent with electron microscopic, x-ra

55 trix protease Ste23 in yeast, a homologue of human insulin-degrading enzyme, which is required for ef

56 Susceptibility to murine and human insulin-dependent diabetes mellitus correlates str

57 ese diabetic mice are a well-known model for human insulin-dependent diabetes mellitus.

58 We apply our protocol to the human insulin dimer (hIns2) as a test case.

59 For example, porcine and human insulin do not stimulate Abs in C57BL/6 mice becau

60 of 3 mm glucose, exogenously added bovine or human insulin do not stimulate endogenous insulin secret

61 In humans, insulin down-regulates the expression of certain

62 adapted an existing commercial kit (Mercodia Human Insulin ELISA, 10-1113-01) to quantify insulin fro

63 The use of ins-asp rather than human insulin enabled us to disentangle exogenous and en

64 ten lack characteristic sequence features of human insulin essential for its folding, structure, and

65 t study, we investigated the contribution to human insulin expression of the GG2 motif found between

66 Analysis of overlapping peptides from human insulin found that insulin B(1-15) bound well to D

67 by the atypical responses of T cells to the human insulin fragment that are described by Kent et al.

68 rmined the cleavage sites and composition of human insulin fragments generated by human IDE.

69 oligonucleotide was demonstrated to capture human insulin from standard solutions and from nuclear e

70 lets by measuring changes in glucose-induced human insulin gene (INS) expression using a single islet

71 em repeats (VNTR) is located upstream of the human insulin gene and correlates with the incidence of

72 uence in the promoter region upstream of the human insulin gene and is widely recognized as a locus o

73 chanism of transcriptional regulation of the human insulin gene by cyclic AMP response element modula

74 engineered to contain multiple copies of the human insulin gene exhibit a large increase in insulin c

75 that AIRE mutation could specifically affect human insulin gene expression in thymic epithelial cells

76 We report 10 heterozygous mutations in the human insulin gene in 16 probands with neonatal diabetes

77 ulin-linked polymorphic region (ILPR) of the human insulin gene promoter region is reported.

78 PDX-1, which binds to four sites within the human insulin gene promoter.

79 nstrate a critical role for the Z element in human insulin gene transcription and its regulation by g

80 was to characterize the effects of FK506 on human insulin gene transcription, insulin mRNA levels, a

81 more reliable reflection of acute changes to human insulin gene transcriptional rates and that glucos

82 ontrolled by the 5' regulatory region of the human insulin gene was decreased in late passage betaTC-

83 A human insulin gene was engineered to allow normal proces

84 an influence transcriptional activity of the human insulin gene, and thus, may contribute to that por

85 llite, located in the promoter region of the human insulin gene, comprises a variable number of tande

86 cells with lentivirus carrying an additional human insulin gene-enhanced secretion twofold.

87 motif, is a site for PDX-1 activation in the human insulin gene.

88 AG4TGTG4/TGTC4ACAC4) located upstream of the human insulin gene.

89 the promoter sequence was isolated from the human insulin gene.

90 ', is located 363 base-pairs upstream of the human insulin gene.

91 ion with the transcriptional activity of the human insulin gene.

92 sfection with combinations of genes encoding human insulin, GLUT2, and glucokinase.

93 cutaneously, [N(epsilon)-palmitoyl Lys(B29)] human insulin had a longer duration of action; a flatter

94 The availability of a DNA ligand to human insulin has analytical importance as well, offerin

95 ated insulin [Lys(B29)-lithocholyl des-(B30) human insulin] has been crystallized and the structure d

96 Although several analogs of human insulin have been developed, the currently prescri

97 minal prolyl and lysyl residues of wild-type human insulin have been inverted, can be crystallized in

98 The structure and dynamics of the R6 human insulin hexamer are investigated by two- and three

99 oach in mapping of disulfide bonds of intact human insulin (HI) and lysozyme.

100 The effects of recombinant human insulin (HI) delivered intraportally or peripheral

101 om C57BL/6 mice primed with either bovine or human insulin in CFA.

102 d insulin analogues were similar to premixed human insulin in decreasing fasting glucose levels, hemo

103 emonstrate T cell proliferative responses to human insulin in IDDM patients.

104 We compared insulin lispro and regular human insulin in the mealtime treatment of 1,008 patient

105 s patient convenience, compared with regular human insulin, in IDDM patients.

106 In group 3 (n = 4), the human insulin infusion was increased to a saturating dos

107 ct injection of PIP peptides 640 or 250 with human insulin into the lumen of rat jejunum caused a dec

108 Furthermore, these cells secrete human insulin into the serum of mice shortly after trans

109 Human insulin is a pivotal protein hormone controlling m

110 Selective capture and release of human insulin is verified using matrix-assisted laser de

111 engineered monomer ([AspB10, LysB28, ProB29]-human insulin) is determined at neutral pH as a template

112 NN304 [Lys(B29)-tetradecanoyl des(B30) human insulin] is a potentially therapeutic insulin anal

113 Insulin lispro [Lys (B28), Pro (B29) human insulin] is a rapidly absorbed analog that has dim

114 ecline in NN304 clearance from plasma as the human insulin level increased (P < 0.05 by ANOVA).

115 nged in the absence and presence of elevated human insulin levels (12.6 plus minus 1.2 vs. 12.4 plus

116 M/islets exhibited euglycemia and detectable human insulin levels (157 muU/mL), whereas no human insu

117 304 concentrations also rose with increasing human insulin levels but did not achieve significance in

118 Human insulin-like growth factor (IGF)-II mRNA has been

119 Mouse models suggest that recombinant human insulin-like growth factor 1 (IGF-1) (rhIGF1) (mec

120 Transgenic mice expressing human insulin-like growth factor 1 (IGF-1) in basal epit

121 Human insulin-like growth factor 1 (IGF-1) is a 70 amino

122 ice were generated in which the cDNA for the human insulin-like growth factor 1B (IGF-1B) was placed

123 The human insulin-like growth factor 2 (IGF2) and insulin ge

124 ture of a metastable folding intermediate of human insulin-like growth factor I (IGF-I) and an engine

125 ntinuous intravenous infusion of recombinant human insulin-like growth factor I (rhIGF-I).

126 Commercial preparations of recombinant human insulin-like growth factor I became available in 2

127 es in the cytoplasmic domain of an oncogenic human insulin-like growth factor I receptor (gag-IGFR) w

128 en developed which binds specifically to the human insulin-like growth factor I receptor (IGF-IR) and

129 domains of the Drosophila insulin receptor, human insulin-like growth factor I receptor, and human i

130 dequate delivery of administered recombinant human insulin-like growth factor I to other tissues, inc

131 Human insulin-like growth factor II gene (IGF2) is overe

132 The human insulin-like growth factor II gene is regulated in

133 The two contiguous IGF2 (human insulin-like growth factor II) and H19 genes are r

134 To improve delivery of human insulin-like growth factor-1 (hIGF-1) to brain and

135 e reported to have resistance to recombinant human insulin-like growth factor-1 (rhIGF-1).

136 tudy, we used transgenic mice overexpressing human insulin-like growth factor-1 exclusively in skelet

137 Treatment with recombinant human insulin-like growth factor-1 restores responses of

138 d accumulation (up to 5.8 fold; P < 0.05) of human insulin-like growth factor-binding protein-3 in mo

139 mac25 propeptide shares a 20-25% identity to human insulin-like growth factor-binding proteins (IGFBP

140 Recombinant human insulin-like growth factor-I (r-HuIGF-I) has been

141 ne encoding a dominant-negative, kinase-dead human insulin-like growth factor-I receptor (IGF-IR) tha

142 ccur following administration of recombinant human insulin-like growth factor-I to the intact animal.

143 Human insulin-like growth factors I and II (hIGF-I, hIGF

144 In contrast to exogenously administered human insulin, LY demonstrated preferential hepatic effe

145 ibe an alternative open reading frame within human insulin mRNA encoding a highly immunogenic polypep

146 les consistently showed the highest level of human insulin mRNA expression and luciferase protein exp

147 kinetics of fibril formation of 20 different human insulin mutants at both low pH (conditions favorin

148 Dogs received 0.36 units/kg s.c. regular human insulin (n = 6) or 1 mg (2.8 units/kg) or 2 mg (5.

149 NN304 (or human insulin) (n = 6 each) was infused at 10.2 pmol cen

150 e that hyperglycaemia impairs the actions of human insulin on umbilical vein endothelial cells isolat

151 ets contained human cells that colabeled for human insulin or PDX-1.

152 and 38 from other sources) if they involved human insulins or insulin analogues, were at least 4 wee

153 ulin analog Lys(B29)-tetradecanoyl des-(B30) human insulin, or NN304, as a marker for insulin transpo

154 sulin were readily differentiated, including human insulin (P28K29) and Lispro insulin (K28P29), whic

155 Cooling of preheated human insulin-poly(ethylene glycol)-water solutions resu

156 We examined the plasticity of human insulin-producing beta-cells in a model of islet c

157 ovision of an unlimited source of functional human insulin-producing cells and 2) prevention of rejec

158 ls, thereby providing an unlimited source of human insulin-producing cells for basic biochemical stud

159 a well-characterized and unlimited source of human insulin-producing cells.

160 mice express SOCS-1 under the control of the human insulin promoter and are on the C57BL6/J backgroun

161 ingly, while Pdx1 responsive elements in the human insulin promoter conform to the pentanucleotide 5'

162 ere observed in transgenic mice containing a human insulin promoter fragment, pointing to the respons

163 does not explain all of the activity of the human insulin promoter in cultured islets, and other tra

164 transfected into primary islet cultures, the human insulin promoter is activated by glucose.

165 Site-directed mutations of the human insulin promoter mapped the low-potency PARP inhib

166 ment between base pairs -341 and -260 of the human insulin promoter, the same region in which a trans

167 n and substitution mutations of the proximal human insulin promoter, we mapped a metabolic response e

168 FK506 decreased HIT cell expression of the human insulin promoter-CAT reporter gene by 40% in the p

169 nt, insulin mRNA levels, and expression of a human insulin promoter-chloramphenicol acetyl transferas

170 ncreatic beta cells under the control of the human insulin promoter.

171 thiazine antipsychotics as modulators of the human insulin promoter.

172 32D myeloid progenitor cells containing the human insulin receptor (32D(IR)).

173 cted with an expression plasmid encoding the human insulin receptor (CHO/HIRc) at concentrations wher

174 overexpression of a dominant-negative mutant human insulin receptor (ESMIRO).

175 levels of native and misfolded forms of the human insulin receptor (hIR) and a human variant found i

176 vectors that the 5'-UTR of the mRNA encoding human insulin receptor (hIR) contains a functional IRES.

177 The cytoplasmic juxtamembrane domain of the human insulin receptor (hIR) contains a single copy of t

178 the folding, assembly, and transport of the human insulin receptor (HIR), a dimeric RTK.

179 t is a monoclonal antibody (MAb) against the human insulin receptor (HIR).

180 starved rat-1 fibroblasts overexpressing the human insulin receptor (HIRc cells) in vivo.

181 Cells overexpressing the normal human insulin receptor (HIRc-B) were used to facilitate

182 rat fibroblast cell line overexpressing the human insulin receptor (HIRc-B), SHIP inhibited membrane

183 Rat1 fibroblasts transfected with wild-type human insulin receptor (HIRcB) and a truncated receptor

184 ial cell (EC)-specific overexpression of the human insulin receptor (hIRECO) using the Tie2 promoter-

185 TMD and intracellular domain of the soluble human insulin receptor (HIRs) with constant domains from

186 eated rat hepatic tumor cell line expressing human insulin receptor (HTC-IR) and livers from lean and

187 covalently to the cytoplasmic domain of the human insulin receptor (IR) beta-subunit when cells are

188 s, we have coexpressed the human IRR and the human insulin receptor (IR) in NIH-3T3 cells.

189 81, compound 1), which induced activation of human insulin receptor (IR) tyrosine kinase and mediated

190 f Chinese hamster ovary cells expressing the human insulin receptor and differentiated 3T3L1 adipocyt

191 imulated tyrosine autophosphorylation of the human insulin receptor and hDIR, and both receptors medi

192 ptor binding to CHO-T cells transfected with human insulin receptor and in vivo metabolic clearance r

193 n Chinese hamster ovary cells expressing the human insulin receptor and murine 3T3L1 adipocytes, insu

194 CHO cells overexpressing the human insulin receptor and rat IRS1 were stimulated with

195 screened with the cytoplasmic domain of the human insulin receptor as bait.

196 he function of a chimeric DIR containing the human insulin receptor binding domain (hDIR) was investi

197 This extension is absent from the human insulin receptor but resembles a region in insulin

198 tations in the tyrosine kinase domain of the human insulin receptor frequently result in a dominantly

199 a subunits in the (alpha beta)2 dimer of the human insulin receptor have been identified by labeling

200 he affinity of N-lithocholyl insulin for the human insulin receptor is not significantly diminished.

201 In contrast, transfection of malfunctioning human insulin receptor mutants, identified originally fr

202 f Chinese hamster ovary cells expressing the human insulin receptor resulted in a time-dependent decr

203 A resolution of an amino-terminal segment of human insulin receptor substrate 1 that encompasses its

204 ry with phosphorylated baculovirus- produced human insulin receptor substrate 1.

205 The human insulin receptor substrate-1 (hIRS-1) is a key int

206 The most commonly detected polymorphism in human insulin receptor substrate-1 (IRS-1), a glycine to

207 IRS-1 was required by the human insulin receptor to activate PI 3-kinase and p70s6

208 for their abilities to selectively activate human insulin receptor tyrosine kinase (IRTK).

209 screen for small molecules that activate the human insulin receptor tyrosine kinase, a nonpeptidyl fu

210 ucture of the purified, functionally active, human insulin receptor using negative stain and cryo-ele

211 r, we incubated CHO cells overexpressing the human insulin receptor with an antibody to the extracell

212 n Chinese hamster ovary cells expressing the human insulin receptor, both proteins display a diffuse,

213 sis was evaluated directly using recombinant human insulin receptor, hamster beta 2-adrenergic recept

214 n Chinese hamster ovary cells expressing the human insulin receptor, insulin causes decreased phospho

215 hamster ovary cells expressing the wild-type human insulin receptor, mock-transfected cells, cells ex

216 ock MA20 binding to its natural antigen, the human insulin receptor, on lymphocytes.

217 g the cytoplasmic kinase domain (CKD) of the human insulin receptor, we demonstrate that autophosphor

218 f the 83-14 monoclonal antibody (mAb) to the human insulin receptor, which is tagged with streptavidi

219 n insulin-like growth factor I receptor, and human insulin receptor-related receptor.

220 terminants, INS-6 binds to and activates the human insulin receptor.

221 on in NIH-3T3 fibroblasts overexpressing the human insulin receptor.

222 transmembrane and cytoplasmic domains of the human insulin receptor.

223 ciation of a serine kinase activity with the human insulin receptor.

224 R, a fibroblast cell line overexpressing the human insulin receptor.

225 sine phosphorylated in vitro by the isolated human insulin receptor.

226 on by insulin in NIH3T3 cells overexpressing human insulin receptor.

227 ovary (CHO) cells that overexpress wild-type human insulin receptors (CHO-hIR-WT) or mutant insulin r

228 hamster ovary (CHO) cells overexpressing the human insulin receptors (CHO/HIRc cells).

229 from Chinese hamster ovary cells expressing human insulin receptors (CHO/IR).

230 CHO cells expressing the human insulin receptors (IR) were used to evaluate the e

231 activity in Rat 1 fibroblasts overexpressing human insulin receptors (Rat 1 HIR cells).

232 inese hamster ovary (CHO-T) cells expressing human insulin receptors and COS-1 cells in response to i

233 inese hamster ovary cells (CHO-T) expressing human insulin receptors causes an 8-10-fold increase in

234 Rat-1 fibroblasts that overexpresses normal human insulin receptors, binding of the GTP analogue GTP

235 oporation into Rat1 fibroblasts that express human insulin receptors.

236 reover, the CTL primed with either bovine or human insulin recognize an A-chain peptide that is ident

237 Human insulin reduced the elevated rates of L-arginine t

238 d the contribution of variation in SORCS1 to human insulin-related traits in two distinct Mexican-Ame

239 Three novel human insulin-releasing cell lines designated 1.1B4, 1.4

240 amide, or PD128763 increased expression of a human insulin reporter gene suppressed by elevated gluco

241 ation in two complementary in vivo models of human insulin resistance (endothelial specific and whole

242 ously hypertensive (SHRSP) rat is a model of human insulin resistance and is characterized by reduced

243 abolic and signaling changes associated with human insulin resistance and provides a genetically amen

244 Based on these data, we propose that human insulin resistance involves a defect in GLUT4 traf

245 Identifying markers of human insulin resistance may permit development of new a

246 icate resistin in the pathophysiology of the human insulin resistance syndrome, an effect mediated by

247 y hypertensive rat (SHR) is a model of these human insulin resistance syndromes.

248 m by which TNF may play an important role in human insulin resistance.

249 The human insulin-resistance syndromes, type 2 diabetes, obe

250 and may be important in the pathogenesis of human insulin-resistance syndromes.

251 r the treatment of type 2 diabetes and other human insulin-resistant states in the future.

252 Overexpression of human insulin-responsive aminopeptidase/oxytocinase resc

253 unogenicity of insulin lispro versus regular human insulin (RHI) in patients previously treated with

254 Overexpression of SOX4 in the human insulin-secreting cell EndoC-betaH2 interfered wit

255 NES2Y is a proliferating human insulin-secreting cell line that we have derived f

256 excess glucose or lipid influence mouse and human insulin secretion and beta cell activity and show

257 In humans, insulin sensitivity varies according to time of

258 o the differential sensitivity of bovine and human insulin-specific CD4+ T cells.

259 ific CD4(+)T cells and demonstrate efficient human insulin-specific Foxp3(+)Treg-induction upon subim

260 In humans, insulin-stimulated PAK activation was decreased

261 response to [N(epsilon)-palmitoyl Lys(B29)] human insulin support the development and further testin

262 Further, human insulin suppressed mosquito immunity through susta

263 tal composition comprising 75% C8-HI and 25% human insulin that exhibits near-ideal basal pharmacodyn

264 s less with insulin lispro than with regular human insulin therapy during three of four quarters of t

265 ined by direct gene fusion of a single-chain human insulin to human serum albumin.

266 ting analog, [N(epsilon)-palmitoyl Lys(B29)] human insulin, to serum albumin in vitro, and the time a

267 addition of 100 nm bovine insulin or 500 nm human insulin together with 3 mm glucose had no stimulat

268 Overexpression of ins-1, or expression of human insulin under the control of ins-1 regulatory sequ

269 e used to extend the time action of insulin, human insulin was acylated at the epsilon-amino group of

270 Human insulin was administered to 13 beagles via inhalat

271 uman insulin levels (157 muU/mL), whereas no human insulin was detected in the islet-only transplanta

272 Regular human insulin was infused (0.28 pmol x m(-2) x min(-1))

273 In group 2 (n = 6), starting at time 0, human insulin was infused at a pharmacologic dose (60 pm

274 ted immediately before the meal, and regular human insulin was injected 30-45 min before the meal.

275 The mass transfer kinetics of human insulin was investigated on a 50 mm x 2.1 mm colum

276 In addition, human insulin was not detected in the serum of SCID-hu m

277 s compared with untreated diabetic mice, but human insulin was not detected.

278 n for the anti-relaxin antibody, whereas the human insulin was transformed into a bona fide relaxin.

279 nous glucose production (EGP) in nondiabetic humans, insulin was infused at rates of 0.25, 0.375, or

280 proteolytic processing to CpepGFP and native human insulin, which are specifically detected and cosec

281 Human insulin, which consists of disulfide cross-linked

282 ne Hagedorn) crystalline complex formed with human insulin, which is commonly used as the long-acting

283 The new route affords human insulin with a yield of 68 % based on the starting

284 ether the isolated A and B chain peptides of human insulin would form fibrils at neutral and acidic p